Pfizer’s COVID-19 vaccine, explained

This appeared in The Millennial Source

Though Pfizer’s trial results are undoubtedly good news, it will not bring the coronavirus pandemic to a sudden halt. People must remain vigilant and take precautions.

After a year in which most of the global community has had to learn — with varying degrees of success — to live with the COVID-19 pandemic, the first truly promising signs of a COVID-19 vaccine are beginning to show.

American pharmaceutical giant Pfizer Inc., in collaboration with its German partner and vaccine developer BioNTech SE, has announced that the preliminary results of its vaccine show that it is more than 90% effective in preventing transmission of COVID-19 among trial volunteers.

With no side-effects yet reported and an efficacy rate far above the 50% required for emergency authorization, Pfizer’s and BioNTech’s development is the first major breakthrough in the global race for a COVID-19 vaccine.

Though Pfizer’s trial results are undoubtedly good news, it will not bring the coronavirus pandemic to a sudden halt. People must remain vigilant and take precautions.

The United States recently passed 10 million confirmed COVID-19 cases. With a widespread rollout of any potential vaccine still months away, the “very dark winter” highlighted by…